Tag: Therapeutics
Vera Therapeutics, Inc. (VERA): A Bull Case Theory
Vera Therapeutics, Inc. is a clinical-stage biotechnology company that has caught the attention of investors due to its…
Gene therapy startup Altido Therapeutics takes aim at glioblastoma brain tumors
Nick Leschly, the well-known CEO in the gene therapy field, is making a comeback with his new company,…
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M
Healthcare company HRTX recently announced their impressive growth in the fourth quarter of 2025, citing the success of…
Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts?
C4 Therapeutics Inc. (NASDAQ: CCCC) is gaining attention as one of the best biotech penny stocks to buy…
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock?
Contrarius Investment Management, an investment management company, recently released its third-quarter investor letter for the “Contrarius Global Equity…
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing cell and exosome-based therapeutics for diseases…
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
A prominent and seasoned company in the healthcare industry appears to be interested in acquiring the biotech firm.…
Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger
We have recently featured a piece titled 10 Major Players With Significant Gains; 6 Reach All-Time Highs. Among…
Biotech Startup Tahoe Therapeutics Raised $30 Million To Build AI Models Of Living Cells
Tahoe Therapeutics, a biotech startup co-founded by Kevin Shokat, Nima Alidoust, Johnny Yu, and Hani Goodarzi, is making…
MIT Spinout Strand Therapeutics Raises $153 Million To Make Cancerous Tumors Light Up
Jake Becraft, a former grad student in biological engineering at MIT, had a groundbreaking idea that could revolutionize…
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) has been identified as one of the top debt-free stocks to invest in right…
Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
Wedbush analyst Laura Chico recently adjusted the firm's price target on Edgewise Therapeutics (EWTX) from $40 to $35,…